Gouty kidney disease: a tubulointerstitial paradigm reimagined-early detection, precision stratification, and targeted intervention.

Authors

Li-Min Liu, Li Qin, Feng Shao

Published in

Rheumatology international. Volume 46. Issue 7. Jun 26, 2026. Epub Jun 26, 2026.

Abstract

Gouty kidney disease is a subtype of chronic kidney disease (CKD) featuring tubulointerstitial injury caused by urate crystal deposition. Conventional assessments using eGFR and albuminuria cannot detect early tubular damage. Risk stratification tools specific to this condition are lacking. We performed a comprehensive literature search from January 2000 to June 2026 across PubMed, Scopus, Web of Science, DOAJ, CNKI, and Wanfang Data. Keywords included gouty kidney disease, tubular biomarkers, SGLT2 inhibitors, and risk stratification. Renal resistive index (RI), urinary α1-microglobulin, and eGFR slope show potential for identifying early tubular injury. SGLT2 inhibitors provide renoprotective and mild urate-lowering effects relevant to gout-related CKD. The Tubular Risk Stratification (TRS) system is proposed as an exploratory, unvalidated conceptual model. A tubule-centred strategy may improve early detection and management of gout-related renal injury. If validated, the TRS system could support risk-stratified clinical care.

PMID:
42362828
Bibliographic data and abstract were imported from PubMed on 13 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.